Theriva Biologics (TOVX)

• Market cap: $6.42M
• 1 day: -3.49%
• 5 days: -7.83%
• 1 month: -8.16%
• 3 months: -44.44%
• 6 months: -57.79%
• Year to date: -30.23%
• 1 year: -85.94%
• 5 years: -99.91%
• 10 years: -100%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Employees: 22